Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Generic Pharmaceutical Association

- PMLiVE

Independent consultant will review Lilly’s COVID-19 plant issues

COVID-19 antibody trial was paused last week due to safety issue

- PMLiVE

Regeneron scores first FDA approval for Ebola antibody treatment

Treatment cut mortality rate in study based in the Democratic Republic of Congo

- PMLiVE

Regeneron seeks US emergency use authorisation for COVID-19 antibody cocktail

If approved, the US government will make initial doses available at no cost

- PMLiVE

FDA publishes new guidelines for COVID-19 vaccine approval

New rules mean a COVID-19 shot is unlikely to be approved pre-election in the US

- PMLiVE

Lilly seeks US emergency approval after posting new data for COVID-19 antibodies

Combination of two antibodies reduced viral load and symptoms of COVID-19

- PMLiVE

Moderna CEO says COVID-19 vaccine will be ready for FDA submission in late November

Company will seek emergency use authorisation for experimental vaccine

AstraZeneca AZ

Japan resumes AZ’s COVID-19 vaccine trial, but US study remains on hold

Trials have also resumed in the UK, India, South Africa and Brazil

- PMLiVE

American Medical Association calls for COVID-19 vaccine development transparency

Organisation asks FDA to provide transparent information on review plans

- PMLiVE

FDA grants emergency approval for blood plasma treatments for COVID-19

Emergency approval granted despite concerns from top US health officials

- PMLiVE

FDA fast-tracks Pfizer/BioNTech’s COVID-19 vaccine candidates

Two investigational candidates granted accelerated review

- PMLiVE

FDA green lights rapid coronavirus diagnostic test

Test can diagnose positive cases in approximately 45 minutes

- PMLiVE

FDA maintains COVID-19 therapeutics must meet a ‘gold standard’

Comes after President Trump called for expedited approval of potential treatments

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links